Drug Database
OM

omeprazole (Omez Insta)

✓ Approved

Dr.Reddy's Laboratories Ltd. · ATP4A · 小分子

什么是 omeprazole?

omeprazole 是一种小分子,由Dr.Reddy's Laboratories Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Omez Insta
公司Dr.Reddy's Laboratories Ltd.
药物类别小分子
分子靶点ATP4A
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

omeprazole 作用于 1 个分子靶点:

ATP4AATPase H+/K+ transporting subunit alpha (ATP6A)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

omeprazole 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersGastritis✓ Approved

相关研究文献

PubMedChirality2026-11-18

Immobilized (L)-Phenylalanine on Tetra-Arm Amino-Terminated Polyethylene Glycols Serve as the Chiral Selector in Liquid-Liquid Extraction for the Resolution of Omeprazole Racemate.

Yang Jiaxing J, Lu Qiang Q, Chen Jiaen J, Yang Kedi K et al.

In this work, we successfully synthesized a chiral selector using (L)-phenylalanine ((L)-Phe) as the chiral building block, along with tetra-arm amino-terminated polyethylene glycols (4-arm PEG-NH2) as the molecular carrier that links (L)-Phe to inhibit the random movement of (L)-Phe molecules in solution. When compared to free (L)-Phe molecules, both 1H NMR spectra and molecular simulations indicate that this design approach creates stronger diastereomeric interactions between the resulting (L)-Phe@4-arm PEGs and S-omeprazole, thereby significantly enhancing the chiral recognition of (L)-Phe@4-arm PEGs towards the enantiomers of omeprazole. This study resulted in the development of a new chiral selector for the resolution of racemic omeprazole, which enabled enantioselective enrichment of S-omeprazole. Enantioselective separation of the two omeprazole enantiomers was achieved by the enantioselective liquid-liquid extraction (ELLE) process with (L)-Phe@4-arm PEGs as the chiral selector. One-step liquid-liquid extraction resolution achieved an enantiomeric excess of about 56% (at 25°C) under optimal conditions.

PMID 43052203
阅读全文 →
PubMedRevista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)2026-11-16

First report of flare-up phenomenon during bismuth subcitrate provocation test.

García Jimena Laiseca JL, Mazuecos Juan María Beitia JMB, Violán Victoria Villalobos VV, Trujillo María Jesús Trujillo MJT et al.

Immediate hypersensitivity to bismuth subcitrate is rare, and established diagnostic protocols are scarce. A 28-year-old female patient with no history of drug allergies presented with malaise, nausea, pruritus, urticaria on the arms, and eyelid edema after taking a dose of Pylera® (bismuth/metronidazole/tetracycline) and omeprazole; symptoms resolved after three days following treatment with antihistamines and corticosteroids. Two months later, skin tests (prick and intradermal tests) for metronidazole, omeprazole, and doxycycline were negative. Tests with Pylera® and bismuth subcitrate caused erythema, raising suspicion of an irritant reaction. Tests with the excipient polyethylene glycol were also negative. A graded oral provocation test with bismuth subcitrate was performed; 30 minutes after the final dose, lesions appeared in the axillae and groin, accompanied by a reactivation reaction (flare-up) at the site of the previous bismuth skin tests. The diagnosis of allergic hypersensitivity to bismuth subcitrate was confirmed, while the other components and the suspicion of an irritant reaction were ruled out. Recognizing immediate hypersensitivity syndrome to bismuth subcitrate provides additional evidence for establishing drug causality during allergological evaluation and assists clinicians in interpreting similar findings during the investigation of drug hypersensitivity. Based on the foregoing, further studies are needed to determine the clinical relevance of immediate hypersensitivity syndrome to bismuth subcitrate.

PMID 43037221
阅读全文 →
PubMedJournal of separation science2026-11-15

Rapid Determination of Esomeprazole by Chiral Capillary Electrophoresis Using Dual-Programmed Voltage and Pressure.

Yun Jihyun J, Jung Hyunjin H, Sohn Seil S, Kang Seong Ho SH

Accurate quantification of (S)-omeprazole is essential to ensure the quality, efficacy, and safety of pharmaceutical formulations. In this study, a chiral capillary electrophoresis (CE) method using dual-programmed voltage and pressure was developed for the rapid determination of (S)-omeprazole, overcoming the inherent trade-off between speed and separation efficiency in conventional CE methods. Under the optimized dual-programmed, stepped chiral CE condition (28 kV + 0.69 kPa, 0-6 min → 25 kV, 6-11 min → 20 kV, 11-14 min → 28 kV + 1.38 kPa, 14-20 min), (S)- and (R)-omeprazole were separated within 12.4 min with a resolution of 2.21. The method showed good linearity over an (S)-omeprazole concentration range of 25-250 µM (correlation coefficient, R = 0.9969), with a limit of detection of 25 µM. The method was successfully applied to a commercial tablet formulation, and a t-test revealed no statistically significant difference between it and prepared standard solutions at the 95% confidence level. Compared with conventional high-performance liquid chromatography methods designed for assay and organic impurity testing, the proposed CE method enables rapid routine chiral assay of (S)-omeprazole while maintaining baseline enantioseparation. These results demonstrate the suitability of the chiral CE method for the routine chiral assay of (S)-omeprazole in pharmaceutical formulations.

PMID 43032896
阅读全文 →
PubMedInternational urology and nephrology2026-11-15

Comparative analysis of kidney adverse events associated with four commonly used proton pump inhibitors based on the PersADE database.

Guo Xianyang X, Chen Peizhen P, Chen Rujie R, Jin Shengwei S

Proton pump inhibitors (PPIs) are widely prescribed, yet their association with kidney injury has drawn increasing concern. Using the PersADE database, we compared kidney adverse drug event (ADE) signals for four oral PPIs (omeprazole, esomeprazole, lansoprazole, pantoprazole) and described reporting patterns by age, body weight, and sex for omeprazole and esomeprazole. In this retrospective pharmacovigilance disproportionality analysis, we retrieved spontaneous reports of nine predefined MedDRA kidney ADE categories with PPIs as the primary suspected drug. Signal detection employed reporting odds ratio (ROR) and proportional reporting ratio (PRR), with positive signals defined as case count ≥ 3, ROR ≥ 2, PRR ≥ 2, and χ2 ≥ 4. Subgroup analyses were descriptive and hypothesis-generating; no formal statistical testing or adjustment for confounders was performed. Due to high missing rates for demographic variables, subgroup analyses were limited to omeprazole and esomeprazole. All four oral PPIs generated positive kidney ADE signals across multiple categories. However, pantoprazole showed no detectable signals for Acute tubular necrosis, chronic kidney disease-mineral and bone disorder or renal cancer. Higher reporting counts were observed in patients aged ≥ 70 years and those weighing > 80 kg, whereas sex was not associated with appreciable differences in reporting counts. All four PPIs exhibit clear kidney ADE signals. The subgroup findings are descriptive and hypothesis-generating rather than established risk factors. These findings suggest that clinicians may consider caution and renal function monitoring in elderly or overweight patients, although further validation is needed.

PMID 43034236
阅读全文 →
PubMedChemistry & biodiversity2026-11-15

Metabolite Profiling and Molecular Docking-Based Validation of Anti-Ulcer Polyphenols From Ajwa Date (Phoenix dactylifera L.).

Kharal Sadia S, Siddique Farzana F, Arshad Muhammad M, Khan Shafaat Yar SY et al.

This study evaluated the anti-ulcer potential of hydroethanolic extracts and solvent fractions of Ajwa date (Phoenix dactylifera L.) and validated their activity through molecular docking. Whole fruit, pit, and flesh were assessed for phytochemical composition using preliminary screening, total phenolic content (TPC), total flavonoid content (TFC), and HPLC profiling. Whole fruit and pit extracts were selected for in vivo evaluation using an ethanol-induced gastric ulcer model in mice. Extracts were administered orally at 250, 500, and 1000 mg/kg for 14 days, with omeprazole (30 mg/kg) as the standard and distilled water as the control. Gastric ulceration was induced using 95% ethanol (0.15 mL/20 g). Ulcer index, gastric pH, plasma gastrin and histamine, mucin levels, and histopathological changes were evaluated. Ethanol treatment caused severe mucosal injury, with an ulcer index of 8.4 ± 0.6. The 60% hydroethanolic whole-fruit fraction significantly (p < 0.05) reduced ulceration, restored gastric pH to 4.8 ± 0.87, increased mucin secretion, and decreased gastrin and histamine levels, achieving 73.7% ulcer inhibition. Molecular docking showed strong binding of quercetin to H. pylori urease (1E9Z) and human pepsin (1PSO), with binding energies of -7.5 and -7.4 kcal/mol, respectively. Ajwa date demonstrated promising anti-ulcer activity associated with its polyphenolic constituents.

PMID 43032964
阅读全文 →
PubMedAnimals : an open access journal from MDPI2026-11-14

Omeprazole Exposure Before Referral in Dogs with Chronic Inflammatory Enteropathy: A Retrospective Observational Single-Centre Study.

Norman Amy A, Walton-Clark Michelle M

Omeprazole, a proton pump inhibitor, is widely used in veterinary medicine, although it may be frequently prescribed for conditions in which evidence of benefit is limited. This retrospective observational single-centre study evaluated omeprazole exposure before referral in dogs subsequently diagnosed with chronic inflammatory enteropathy. Medical records from 151 dogs were reviewed, including omeprazole exposure during the six months preceding referral, documented indication, dose and administration frequency. Indications were classified according to American College of Veterinary Internal Medicine consensus recommendations. Overall, 83/151 dogs (55.0%; 95% CI, 47.0-62.7%) had documented omeprazole exposure within six months of referral. Of these, 30/83 (36.1%; 95% CI, 26.6-46.9%) had a documented consensus-consistent indication, whereas 53/83 (63.9%; 95% CI, 53.1-73.4%) did not. Non-specific gastrointestinal signs were the most common documented indication (42/83; 50.6%), followed by suspected gastrointestinal bleeding or gastrointestinal ulceration or erosion (21/83; 25.3%) and suspected gastro-oesophageal reflux or reflux-associated oesophagitis (9/83; 10.8%). Among dogs with a clearly documented once or twice daily oral dosing regimen, once daily administration was more common than twice daily administration (38/65; 58.5% versus 27/65; 41.5%). Omeprazole exposure was common before referral, and a substantial proportion of exposed dogs had no documented indication consistent with ACVIM consensus recommendations. Interpretation was limited by the retrospective design and dependence on the completeness of referring veterinary clinical records.

PMID 43027112
阅读全文 →

注册免费账户还可查看另外 9756 篇文献

免费注册查看全部文献 →

了解更多omeprazole